Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort ascending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Zemaira Alpha1-proteinase inhibitor (Human) Severe Alpha1-proteinase inhibitor deficiency Reimburse with clinical criteria and/or conditions Complete
Zeldox Ziprasidone hydrochloride Schizophrenia and related psychotic disorders List with clinical criteria and/or conditions Complete
Zelboraf Vemurafenib Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Zejula Niraparib Ovarian Cancer Reimburse with clinical criteria and/or conditions Complete
Zejula Niraparib First Line OC Reimburse with clinical criteria and/or conditions Complete
Zaxine Rifaximin Hepatic encephalopathy List with criteria/condition Complete
Zavesca Miglustat Gaucher disease Do not list Complete
Zaltrap Aflibercept Metastatic Colorectal Cancer Do not reimburse Complete
Yondelis Trabectedin Metastatic Liposarcoma or Leiomyosarcoma Do not reimburse Complete
Yescarta axicabtagene ciloleucel Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) Reimburse with clinical criteria and/or conditions Complete